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lacking affinity for G"r was markedly reduced when administered nasally to mice
(Chapter 6). In addition, we demonstrated that also for the potent immunogenicity of
LT, Gn,,-binding affinity is essential (Chapter 6). We were the first to show that wild-
type LT and a nontoxic LT mutant induce comparable LTA-specific serum and
mucosal antibody responses (Chapter 7). On the other hand, when mice were
immunized with LTA alone, no antigen-specific antibodies were induced, indicating
that linkage to the B-pentamer is essential for the immunogenicity of LTA.
Taken together, the above results indicate that the potent immunogenicity of LT
stems primarily from its capacity to bind with high affinity to the G* ganglioside,
present on mucosal epithelial cells. This ensures efficient cellular uptake of the toxin.
After transcytosis, the B-pentamer probably interacts directly with antigen-
presenting cells, and B and T cells, resulting in activation of Gr,-coupled signal
transduction pathways within these cells. This eventually results in modulation of
the mncosal immune response (see also section 2.2).ln case of the LT/CT holotoxin,
the A subunit probably influences the immune-stimulatory process upon Gr,-
binding-mediated internalization of the toxin. It is likely that this immune-
stimulatory mechanism is similar to that involved in adjuvanticity of LTA (as
described below). Also, T-helper epitopes of the A subunit may influence the
induction of antitoxin antibody responses. However, further characterization of the
structure-function relationships of the A subunit is required to cielineate which
properties, epitopes, or amino acid residues are essential for immune stimuiation by
LTA. Such studies would involve the evaiuation of the immunogenicity of LT(A)
variants in which mutations have been placed at random, or LT(A) deletion mutants.
2. LT and LT subunits as mucosal immunoadjuvants
2.1Role of the individual subunits in adjuvanticity of LT
Most adjuvant studies with bacterial enterotoxins (LT, CT, PT, etc) have been
performed with CT. However, more recent studies have also focussed on LT, mainly
because LT is less toxic than CT; in addition, the structure-function relationships of
LT have been studied with aid of the known 3D-structure of the molecule (270-212),
while the 3D-structure of CT has only recently become available (763,273,274). At the
beginning of this study, the role of the individual subunits in the immunoadjllvant
properties of LT/CT was not clear. Especially results obtained with commercially
available and recombinant CTB/LTB were highly inconsistent (47,98,740,146,228-236,
258). In addition, more recent results obtained with LTICT mutants, lacking ADP-
ribosylation activity, have been contradictory as well. While Lycke et aI. (146) showed
that the nontoxic LT-E112K mutant lacks adjuvant activity, several other
investigators have demonstrated that different rLontoxic LTiCT mutants retain
adjuvanticity (60,67,63,277,272). With respect to the role of ADP-ribosylation activity,
we unambiguously demonstrate that the enzymatically inactive LT-E112K mutant
completely retains the adjuvant properties of wild-type LT upon intranasal
administration to mice (Chapter 4, 5,8). This adjuvant activity not only pertains to
the induction of strong serum IgG responses to coadministered antigens, but also to
the induction clf brisk S-IgA responses in mucosal secretions. Thus, clearly, ADP-
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ribosyltransferase activity of LTA is not essential for the adjuvant properties of LT
towards admixed antigens. This is in agreement with recent publications on the
adjuvant activity of nontoxic LT /Cf mutants (60,67,63,277,272). On the other hand,
Lycke et al. (146) observed that LT-E112K lacks adjuvant activity towards orally
administered KLH. We suspect that the route of immunization, intranasal vs. oral, is
responsible for this discrepancy. In fact, none of the nontoxic LT mutants described
thusfar, has been administered via the oral route to result in generalized mucosal
immune responses. There is a growing awareness that indeed for induction of
generalized mucosal immune responses intranasal immunization is more efficient
than oral immunization (266). Possible explanations for this phenomenon are: (i)
more efficient uptake of antigens in the nasal cavity, due to a lower total antigen
load; (ii) a milder physiological environment in the nasal cavity compared to the gut,
where antigens may be degraded by acid pH or proteolytic activity; and, (iií)
differences in the nasal (NALT) and gut-associated lymphoid tissue (GALT). With
respect to the latter, it is clear that there are differences in the T/B cell,
naive/memory T cell, and CD8./CD4. T cell ratios in NALT and GALT (725,265,266).
This suggests that compared to GALT, mucosal immune responses in NALT are
induced and regulated differently. The fact that recently CT-Ei12K was founcl to be
an effective adjuvant upon subcutaneous administration (271.), supports our view
that indeed the route of immunization is crucial for the outcome of the experiment.
The results described in Chapter 4,5, and 8 clearly show that recombinant LTB has
bona fide adjuvant activity. Recombinant LTB induced both strong serum and
mucosal antibody responses towards a variety of coadministered antigens.
Furthermore, the observed antibody responses were comparable to those obtained
with either LT-E112K or wild-type LT. Therefore, it is clear that neither the ADP-
ribosylation activity of LTA, nor the pÍesence of LTA is essential for effective
immune stimulation. While most investigators have found that recombinant
LTBICTB lack adjr.rvanticity (41,140,1.46,271,272), several others observed the
opposite (64,98). This may be explained by the fact that the majority of these studies
were performed using the oral route of administration, while only in a few cases
adjuvanticity of LTB/CTB upon intranasal administration was evaluated. Thus,
again the route of immunization may be crucial. Also, most studies were performed
with CTB, and not with LTB. While CTB binds exclusively to Gvr, LTB also binds to a
variety of other receptors (66,83,704,L05). This different receptor binding capacity is
likely to play a role in the observed adjuvant effect, especially since it was recently
observed that LTB and nontoxic LT mutants are more ootent stimulators of mucosal
immune responses than CTB or nontoxic Cf mutants (64).
To our knowledge, we were the first to study the role of Gno,-binding in the
adjuvant properties of LT and LTB. In general, Grr-binding is considered to be
essential for adjuvanticity. Remarkably, we found that an LT mutant, which lacks
Gr,-binding affinity, acts as a potent adjuvant towards coadministered antigens
(Chapter 6, 8). Furthermore, an LT double mutant, LT-8772K/G33D, lacking both
ADP-ribosylation activity and Gr,-binding activity, also retained adjuvant aciivity
comparable to that of wild-type LT. On the other hand, Gr,-binding is essential for
the adjuvanticity of LTB (Chapter 6, 8). These findings are suggestive of a Gr,'-
binding-independent adjuvant effect of LTA. Furthermore, immune stimulation by














































LTA does not require ADP-ribosylation activity. Interestingly, the immunogenicity of
the non-Grr-binding LT mutants is markedly reduced. This suggests that the mode of
induction of antitoxin antibodies vs. induction of antibodies to coadministered
antigens may be different. Recent studies, involving the use of IL-4 knock-out mice,
appear to support this idea (782,246). While in these mice responses to orally
administered CT were normal, antibody responses to coadministered antigens were
absent. This is probably because the antibody response towards coadministered
antigen is solely dependent on a Th2-type helper response, which is inhibited in the
absence of IL-4, while both Th1- and Th2-type responses support the production of
antitoxin antibodies (182,246).
In agreement with the results in Chapter 6, Chapter 7 and 8 show that LTA by
itself can act as a powerful intranasal mucosal adjuvant towards a coadministered
antigen. Therefore, we are the first to present direct evidence that both the
recombinant A and B subunit of LT have adjuvant activity. Furthermore, by using an
LTA mutant, devoid of ADP-ribosylation activity, we showed that this activity is not
involved in the immune stimulation by LTA (Chapter 8). These findings are in
agreement with and extend the findings of Ágren et al. (2), who showed that a
targeted CTA1 fusion protein has potent adjuvant activity towards intranasally or
intravenously administered antigens. These investigators showed that a CTA1 fusion
protein, composed of CTA1 fused to 2 copies of the D domain of staphylococcal
protein A, has potent adjuvant activity. Furthermore, it was shown that the DD-
moiety targets CTA1 to B cells, which is considered to be the basis of the observed
adjuvant effect. We now demonstrate, that also in the absence of a specific targeting
mechanism, LTA and a nontoxic LTA mutant strongly stimulate antibody responses
towards coadministered antigens. Clearly, this has important implications for the
design of LT/CT variants as vaccine adjuvants. Such strategies have, until now,
focussed mainly on the use of the nontoxic B subunit or nontoxic LT /Cf mutants.
However, we have shown that also nontoxic CTA/LTA variants may be used as
vaccine adiuvants.
Although it is clear that LT is a potent mucosal immunoadjuvant, there appear to
be limitations to its adjuvant properties. We observed that LT failed to induce
mucosal secretory responses against pneumolysin (Chapter 5), a malaria antigen
(TBV2SH), and recombinant HIV gp120 (De l{aan et al., unpublished observations),
upon intranasal administration to mice. At this moment, we do not have an
explanation for the observed antigen-specificity of the adjuvant effect. Possibly, the
physical-chemical properties of the antigen, such as solubility, molecular size or
weight, and hydrophobicity, play a role in the adjuvanticity of LT. However, there
are indications that adjuvanticity of LT towards such antigens can be restored by
coupling antigen and adjuvant, resulting in a targeted antigen/adjuvant complex
(41).
2.2 Mechanism of adiuvanticity of LT and LT subunits
LT and CT are well-recognized mucosal immunoadjuvants. Although we have
established the requirements for adjuvanticity of LT and LTB, the immunological
basis of their adjuvant properties is still poorly understood. Clearly, adjuvant activity
of LTB is directly related to G",-binding affinity (Chapter 6, 8). Therefore, Gr,-
t04
binding.not on-ly mediates efficient uptake of the toxoid, but is also involved in thestimulation of antibody responses directed against coadministered ur-,,ij".,r.Although the exact mechanism of adjuvanticity óf LTB is likeh, 1.l be extremery
complex, two separate stages can be distinguishód: (i)binding of LTB to the mucosal
surface and enhancem€nt 
-of the uptakà of ruminal antiiens, and (ii) specificmodulation of mucosal ."1]{T ."rponr"s towards coadmiristered o.,iig",-r. It i,known that upon binding of CTB to the mucosal cell surface, the permeabiïity of themucosal membrane barrier is enhanced (87,88,745). This facilitites more óffi.i..r",,absorption of antigens coadministered with CTB or LTB. After transcytosis through
mucosal epithelial cells or M-cells, the B pentamer ir-rteracts directly *iínimmunocompetent cells via its Gr,-binding capacity. subsequently, Gr,-coupíed cell_signaling pathways within these cells are activated, eventuàlly rósultiiig in cytokine
expression, selective stimulationof proliferation of CD4- Th2-iype cells,"inhibition ofproliferation andlor apoptosis of CD4- Th1-type and CD8. T cells, and stimuiation ofB cell proliferation. For instance, LTB and tttCt strongly stimulate procluction ofTh2-type cytokines by CD4. T celrs and 
.macrop nages (í+i,t22,226,267,26g,277,272).By binding to the cell surface of B cells ancl mic.ophages, LTB enhances theirantigen-prelenling capacity (79,r43,r74). Also, 
""i."rËior, of co-stimulatorymoiecules ICAM-I, 87,cD2s, and CD40 orr B ceils is ànhanced Èy ui"ai"g 
"r 
iïr,(175)' For most of these effects the requirement for Gn,,-binding has beel 
"ráblirh"dil^t!ld]"_r i"volving the use of LTB ut'rà ctg mutants, which raci Gn,,-bilding affiniiy(73,79,774).
As indicated above, our present results show that also the A subunit alone hasimmunoadjuvant properties, which are independent of ADp-ribosyiatiol altivity.
11"_:*l"ologic.al basis of immunomodulatiàn by LTA alone is not clear. Howe'er.recenily, Agren et al. (2) have shown that CT and CTA1, but not CTB, enhances theexpression of CD80 and CD86 co-stimulatory molecules on B cells. Also, in a recent
study, we demonstrated that LT, LT-8712K, LTB ànd LTA induce ur,trg".,_rp".iri.Igc1, IgG2a 
-and,IgG2b (DeHaan et nr. manuscript in preparatro.). Th.s, thesemolecules induce both Th1 3r_r{ ]rrz-type responses, which support the prodrrction ofthese antibldy subtypes (766,238). Ho*"u"i, the kinetics of iÀductionof especiallyIgC2a by LTA and LTA-E112K is different, indicating that the mode of induction ofmucosal immune responses by LTA alone is diffeient. It is possible that thesemolecules also itrduce altered cytokine profiles. No doubt, determination of these
cytokine profiles, in combination with studies performed in cytokine gene knock-out
T.tt-1,.^ïottld give further insights ir-r the mechanisms of adjuvanticity of LT and itssuDunlts.
3' Perspectives for vaccine development based on the use of nontoxic LT variantsas mucosal immunogens and adjuvants
LT and CT represent imporiant adjuvant candiclates for locally administered



















































































in this thesis that nontoxic variants of LT retain the immunogenic and adjuvant
properties of the wild-type toxin, has important implications for future vaccine
design against cholera, enterotoxigenic Ë. coll (ETEC), and other infectious diseases.
Current experimental ETEC and cholera vaccines are composed of whole
inactivated bacteria, supplemented with recombinant B subunit (:l). attnough the
protective capacity of antitoxin antibodies alone is limited, coadministration of B
subunit clearly improves the efficacy of these vaccines (35). Our studies demonstrate
that LT mutants which lack ADP-ribosylation activity are more immunogenic than
recombinant LTB upon intranasal administration to mice. Fnrthermore, it was
recently shown that a nontoxic LT mutant induced toxin-neutralizing antibodies
against both the A and B subunit (191). Therefore, a promising approach for
improvement of current whole-cell cholera and ETEC vaccines would be replacement
of the B subunit with a nontoxic mutant.
All of the adjuvant studies presented in this thesis have focussed on the direct
measurement of antibocly titers. For the use of LT and LT variants as vaccine
adjur.ants it is crucial to relate these titers to protection against infection with a
mucosal pathogen. Recently, we have evaluated the protective capacity of an
experimental influenza vaccine against a homologous virus challenge (Yerwelj et al.,
manuscript in preparation). The vaccine consisted of influenza subunit antigen
supplemented with either LT or LTB. The obtained results show that in contrast to
mice immunized subcutaneously with subunit antigen (the currently used
immunization procedure), mice that received either the LT or LTB-supplemented
vaccine are completely protected against virus challenge, indicating that the
experimental vaccine offers superior protection (Verwelj et al., manuscript in
preparation). Clearly, the antigen-specific antibody responses induced by LT and LT
variants, presented in this thesis, are relevant for providing protection against
infection with a mucosal pathogen. Therefore, the main conclusion from the work in
this thesis is that nontoxic LT variants, which retain the immunoadjuvant properties
of the wild-type toxin have great potential, and may be used as adjuvants for new-
generation vaccines, which will elicit a moíe broad-spectrum immunity, using the
local route of administration. The use of LT variants as vaccine adiuvants is not
restricted to induction of mucosal respiratory immunity, relevant for pathogens
wtrich enter their host via the respiratorv tract. such as influenza virus and
respiratory syncytial virus. BecausË of t-he existence of generalized mucosal
immunity after intranasal immunization, LT variants may also be used for induction
of immunity against pathogens which enter the host via different mucosal sites. In
this respect, the observation that nontoxic LT variants induce brisk vaginal IgA
responses, offers attractive perspectives for intranasal vaccination against sexually-
transmitted pathogens, such as hepatitis, herpes and human papilloma virus.
